

# Effect of Depth of Sedation in Older Patients Undergoing Hip Fracture Repair on Postoperative Delirium

## The STRIDE Randomized Clinical Trial

Frederick E. Sieber, MD; Karin J. Neufeld, MD, MPH; Allan Gottschalk, MD, PhD; George E. Bigelow, PhD; Esther S. Oh, MD; Paul B. Rosenberg, MD; Simon C. Mears, MD; Kerry J. Stewart, EdD; Jean-Pierre P. Ouanes, DO; Mahmood Jaber, MD; Erik A. Hasenboehler, MD; Tianjing Li, PhD; Nae-Yuh Wang, PhD

**IMPORTANCE** Postoperative delirium is the most common complication following major surgery in older patients. Intraoperative sedation levels are a possible modifiable risk factor for postoperative delirium.

**OBJECTIVE** To determine whether limiting sedation levels during spinal anesthesia reduces incident delirium overall.

**DESIGN, SETTING, AND PARTICIPANTS** This double-blind randomized clinical trial (A Strategy to Reduce the Incidence of Postoperative Delirium in Elderly Patients [STRIDE]) was conducted from November 18, 2011, to May 19, 2016, at a single academic medical center and included a consecutive sample of older patients ( $\geq 65$  years) who were undergoing nonelective hip fracture repair with spinal anesthesia and propofol sedation. Patients were excluded for preoperative delirium or severe dementia. Of 538 hip fractures screened, 225 patients (41.8%) were eligible, 10 (1.9%) declined participation, 15 (2.8%) became ineligible between the time of consent and surgery, and 200 (37.2%) were randomized. The follow-up included postoperative days 1 to 5 or until hospital discharge.

**INTERVENTIONS** Heavier (modified observer's assessment of sedation score of 0-2) or lighter (observer's assessment of sedation score of 3-5) propofol sedation levels intraoperatively.

**MAIN OUTCOMES AND MEASURES** Delirium on postoperative days 1 to 5 or until hospital discharge determined via consensus panel using *Diagnostic and Statistical Manual of Mental Disorders* (Fourth Edition, Text Revision) criteria. The incidence of delirium was compared between intervention groups with and without stratification by the Charlson comorbidity index (CCI).

**RESULTS** Of 200 participants, the mean (SD) age was 82 (8) years, 146 (73%) were women, 194 (97%) were white, and the mean (SD) CCI was 1.5 (1.8). One hundred participants each were randomized to receive lighter sedation levels or heavier sedation levels. A good separation of intraoperative sedation levels was confirmed by multiple indices. The overall incident delirium risk was 36.5% ( $n = 73$ ) and 39% ( $n = 39$ ) vs 34% ( $n = 34$ ) in heavier and lighter sedation groups, respectively ( $P = .46$ ). Intention-to-treat analyses indicated no statistically significant difference between groups in the risk of incident delirium (log-rank test  $\chi^2$ , 0.46;  $P = .46$ ). However, in a prespecified subgroup analysis, when stratified by CCI, sedation levels did effect the delirium risk ( $P$  for interaction = .04); in low comorbid states (CCI = 0), heavier vs lighter sedation levels doubled the risk of delirium (hazard ratio, 2.3; 95% CI, 1.1- 4.9). The level of sedation did not affect delirium risk with a CCI of more than 0.

**CONCLUSIONS AND RELEVANCE** In the primary analysis, limiting the level of sedation provided no significant benefit in reducing incident delirium. However, in a prespecified subgroup analysis, lighter sedation levels benefitted reducing postoperative delirium for persons with a CCI of 0.

**TRIAL REGISTRATION** clinicaltrials.gov Identifier: [NCT00590707](https://clinicaltrials.gov/ct2/show/study/NCT00590707)

*JAMA Surg.* 2018;153(11):987-995. doi:10.1001/jamasurg.2018.2602  
Published online August 8, 2018.

← Invited Commentary  
[page 996](#)

+ Supplemental content

+ CME Quiz at  
[jamanetwork.com/learning](https://jamanetwork.com/learning)  
and CME Questions page  
1068

**Author Affiliations:** Author affiliations are listed at the end of this article.

**Corresponding Author:** Frederick E. Sieber, MD, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Bayview Medical Center, 4940 Eastern Ave, Baltimore, MD 21224 ([fsieber1@jhmi.edu](mailto:fsieber1@jhmi.edu)).

Postoperative delirium (PD) is the most common complication after major surgery in older patients without cognitive impairment.<sup>1</sup> Postoperative delirium carries with it personal, social, and economic burdens.<sup>2</sup> This complication, with its associated costs, will assume increasing importance as the number of older patients in the US population continues to grow.

The mainstay of delirium management is prevention by control and/or elimination of modifiable risk factors. One such risk factor may be sedative medications, as both drug selection and dosage can be modified. The role of sedative and analgesic medications as iatrogenic risk factors for delirium in intensive care unit (ICU) and postsurgical patients is well described.<sup>3-6</sup> The evidence suggests that the level of sedation varies substantially during surgery and that heavier sedation levels that are consistent with general anesthesia are commonplace intraoperatively.<sup>7</sup> Managing intraoperative sedation may be an important modifiable risk factor; however, to our knowledge, few studies have been done in this area.

To help explain the contribution of sedation levels to PD, we undertook a randomized, 2-group, parallel superiority trial called A Strategy to Reduce the Incidence of Postoperative Delirium in Elderly Patients (STRIDE). The primary aim of STRIDE was to compare the effect of lighter and heavier intraoperative propofol sedation levels on delirium incidence in older patients who were undergoing hip fracture repair. A secondary objective was a prespecified subgroup analysis to determine whether limiting sedation levels during spinal anesthesia reduces incident PD when stratified by baseline comorbidity.

## Methods

### Study Design and Participants

The research protocol was approved by the Johns Hopkins institutional review board (NA\_00041873). The trial was registered at ClinicalTrials.gov (NCT00590707) (Supplement 1). All participants provided their written informed consent. STRIDE was conducted at a single clinical center, and all intraoperative management was provided by 4 anesthesiologists. A detailed description of the trial protocol was published previously in the supplemental material of Li et al.<sup>8</sup>

Patients who were 65 years or older who were undergoing hip fracture repair with spinal anesthesia and propofol sedation and who did not have preoperative delirium or severe dementia were randomized to receive either heavier (modified observer's assessment of alertness/sedation score [OAA/S], 0-2) or lighter (OAA/S, 3-5) intraoperative sedation levels.<sup>9</sup> An OAA/S range for each sedation level was felt to more accurately reflect the clinical picture because exact OAA/S targets cannot always be achieved. The inclusion criteria were (1) admission to Johns Hopkins Bayview Medical Center for surgical repair of a traumatic hip fracture, (2) being age 65 years or older, (3) a preoperative Mini-Mental State Examination (MMSE) score of 15 or higher,<sup>10</sup> and (4) receiving spinal anesthesia. The exclusion criteria included (1) receiving general anesthesia, (2) an inability to speak or understand English, (3) severe chronic obstructive pulmonary disease or congestive heart

### Key Points

**Question** Does limiting sedation levels during hip fracture repair under spinal anesthesia reduce postoperative delirium overall or when stratified by baseline comorbidity?

**Findings** In this randomized clinical trial that included 200 older patients randomized to receive lighter vs heavier sedation, limiting levels of sedation provided no significant overall benefit in reducing incident delirium. However, in a prespecified subgroup analysis, heavier vs lighter sedation levels doubled the risk of postoperative delirium in patients with low baseline comorbidities as defined by a Charlson comorbidity index score of 0.

**Meaning** Limiting intraoperative sedation levels may reduce delirium in older patients with low baseline comorbidity.

failure, (4) refusal to give informed consent, (5) a nonparticipating attending surgeon, (6) hip fractures in both hips at the same admission, (7) a repair of another fracture concurrently with the hip fracture, (8) a prior hip surgery on the same hip that would be repaired in the current surgery, and (9) preoperative delirium.

### Outcomes

Patients were assessed for delirium, delirium severity, and cognition preoperatively and on postoperative days 1 to 5 by research personnel who were masked to the randomization assignment. The diagnosis of delirium was made by a multidisciplinary consensus panel based on *Diagnostic and Statistical Manual of Mental Disorders* (Fourth Edition) criteria using several data sources, including the confusion assessment method,<sup>11</sup> the Delirium Rating Scale-Revised-98 (DRS),<sup>12</sup> digit span, a review of medical records, and family/nursing staff interviews. The primary outcome was the incidence of delirium from postoperative day 1 to postoperative day 5 or hospital discharge, whichever occurred first. The secondary outcomes were MMSE scores and DRS severity and total scores during the first 5 postoperative days or until hospital discharge, whichever occurred first. The prespecified secondary objective was to assess the interaction between baseline comorbidity and propofol sedation levels in determining delirium incidence after hip fracture repair (see the protocol in the supplemental material of Li et al<sup>8</sup>).

STRIDE was powered to detect a 48.0% risk reduction in the primary outcome, PD in-hospital up to day 5 after surgery, from 39.6% in the heavier sedation arm to 20.6% in the lighter sedation arm with 80% power using a 2-sided test with a type I error of 0.05 through a sample of 200 participants in equal allocation who were randomly assigned to the 2 study arms.<sup>8</sup> These power assumptions were based on our preliminary randomized clinical trial.<sup>13</sup>

### Statistical Analysis

All analyses were conducted with the intention-to-treat principle. The incidence of delirium in the 2 intervention groups was compared using the time-to-event analytic approach. The cumulative incidence of PD was estimated by a Kaplan-Meier analysis, and the between-group difference

of incidence was compared with the log-rank test. The relative risk of PD between intervention groups was evaluated with Cox proportional hazards models. The proportionality assumption was verified using Schoenfeld residuals and a proportionality test. The secondary outcomes included the tracking of daily MMSE scores, DRS severity, and total scores during the participant's hospital stay using a non-parametric regression. Between-group comparisons were conducted with mixed-effects linear models.<sup>8</sup> The binary outcome of PD that occurred in both intervention groups was evaluated by a logistic regression. All of the modeling approaches accounted for the age and MMSE score at baseline that was used in stratified randomization. Our only pre-planned subgroup analyses explored the heterogeneity of intervention effects by stratifying the study groups according to the Charlson comorbidity index (CCI) score.<sup>14</sup> The CCI score was not age corrected and was calculated as previously described,<sup>14</sup> except that baseline a Clinical Dementia Rating score of 1 or more defined dementia. The treatment interaction with the CCI scores on the time-to-event outcome was tested with a Cox proportional hazards model and accounted for the covariates that were related to the outcome and the CCI scores. Treatment-CCI interactions on the binary outcome of PD were tested by a logistic regression similarly. In these subgroup analyses, we treated the CCI scores as categorical variables in exploratory analyses to identify parsimonious effect modification models. We tested them as a continuous variable that extended through the full range of CCI scores and as a "truncated" variable that combined all scores of 3 or more as more than 2. Baseline characteristics that are associated with PD and CCI scores were adjusted for in these effect modification models, in addition to baseline age and MMSE scores. All analyses were conducted with SAS, version 9.4 (SAS Institute).

## Results

**Figure 1** outlines the Consolidated Standards of Reporting diagram for STRIDE. Of 538 patients with a hip fracture who were screened from November 18, 2011, through May 19, 2016, 200 patients (37.2%) were randomized to receive either lighter or heavier sedation levels. The most common reasons for ineligibility were an age younger than 65 years (97 [18.0%]) and an MMSE score of less than 15 (88 [16.4%]). Of 225 eligible patients who were approached to provide consent, only 10 (4.4%) declined participation; 15 (6.7%) became ineligible between the time of consent and surgery.

### Baseline Characteristics

Baseline demographics were similar in the 2 intervention groups (**Table 1**). Forty-eight participants (24%) had any education beyond high school. The baseline comorbidities, as assessed by CCI scores, and functional status were well-matched between the groups. Sixty-seven (33.5%) and 75 (37.5%) participants were capable of performing all physical self-maintenance scale items and the instrumental activities of daily living items, respectively.<sup>15</sup> One-hundred sixteen (58%)

had a smoking history, and 27 (13.5%) scored 2 or greater on the CAGE<sup>16</sup> alcoholism questionnaire.

The baseline cognitive testing results were comparable between intervention groups. A Geriatric Depression Scale score of 6 or more occurred for 51 participants (25.5%),<sup>17</sup> and 116 (58%) had a Clinical Dementia Rating score of 0.5 or more.<sup>18</sup> The mean (SD) MMSE score for all participants was 24 (4). The type of fracture and surgical procedure, including the use of cement, did not differ between intervention groups (**Table 1**).

### Intervention

Intraoperatively, the separation between groups was good (**Table 2**), as indicated by both modified OAA/S and EEG criteria (Bispectral index; BIS Brain Monitoring System, <http://www.medtronic.com/covidien/products/brain-monitoring>). The sedation scores demonstrate a clinical difference between lighter (OAA/S ~ 4 represents a lethargic response to calling a name in a normal tone) vs heavier sedation levels (OAA/S ~ 0 occurs when the participant does not respond to noxious stimuli). The bispectral index values reflect the same clinical differences as the OAA/S scores. As expected, the heavier sedation group received a higher total propofol dose. No intraoperative narcotics or benzodiazepines were administered to any patient. Patients in the heavier sedation group had longer surgical times secondary to prolonged awakening. Intraoperative mean arterial pressure was lower in the heavier sedation group secondary to the cardiovascular depressant effects of propofol. The overall level of spinal anesthesia was T9 ± 1.5 dermatomes. Most blood transfusions occurred postoperatively within 72 hours, with only 4 patients (2%) receiving intraoperative transfusions.


### Patient Follow-up

Postoperative ICU admission rates, opioid consumption, and pain scores were similar in the 2 intervention groups (**Table 2**). All patients who were admitted to the ICU postoperatively had a 1-day length of stay. No patients in the ICU required intubation. The postoperative length of stay and hospital discharge location were comparable between intervention groups. There was no difference between groups in incidence or type of complications during the first 30 postoperative days.

### Effect of Intervention on Incident PD

Without adjusting for comorbidities, the incidence of a delirium diagnosis at any time during postoperative days 1 to 5 was 39% (n = 39) in the heavier sedation group and 34% (n = 34) in the lighter sedation group (P = .46, by  $\chi^2$  analysis). The overall incidence was 36.5% (n = 73). Although we observed consistently less PD in patients who received lighter sedation levels, the difference between groups was not statistically significant. An intention-to-treat analysis showed no statistical difference between groups in incident PD, total days of PD, or total days of PD + subsyndromal symptoms (**Figure 2**). Secondary outcomes showed that DRS severity was higher and MMSE scores were lower in the heavier sedation group on postoperative day 1 (eFigure in **Supplement 2**).

Figure 1. Consolidated Standard of Reporting Diagram for STRIDE Study



Patients were recruited between November 18, 2011, and May 19, 2016. JHBMC indicates John Hopkins Bayview Medical Center; MMSE, Mini-Mental State Examination.

### Interaction Between Comorbidity and Intervention in Determining Incident PD

Incorporating a model that was adjusted for covariates that were associated with PD in the literature<sup>19,20</sup> and this data set (age, MMSE score, fracture type, Geriatric Depression Scale score) revealed significant interaction between sedation levels and CCI in determining PD. Significant interactions occurred in the time-to-event outcome in the form of hazards ratios that were associated with the intervention from the Cox regression models as well as the risk in the binary outcome of ever receiving a diagnosis of PD (Figure 3). In patients with a baseline CCI score of 0, heavier sedation levels doubled the risk of PD (hazard ratio, 2.3; 95% CI, 1.1-4.9). In patients with higher baseline comorbidity, as indicated by a CCI score of more than 0, the level of sedation was not related to incident PD (eTables 1-4 in Supplement 2).

### Discussion

The overall intention-to-treat analysis, without considering comorbidity, showed no statistically significant benefits of lighter sedation levels during hip fracture repair under spinal anesthesia. However, secondary analyses that incorporated the consideration of comorbidities suggested that this lack of overall effect may be due to the heterogeneity of treatment effects (HTE) that was associated with baseline comorbidity. Pre-planned secondary analyses for HTE showed that comorbidities may modify the treatment effect of sedation levels on PD risk in this older population with hip fracture. Lighter sedation levels were associated with lower PD incidence, but the difference from the heavier sedation group was statistically significant only in the subgroup with less comorbidity. At higher levels of comorbidity, the benefit of lowering PD risk by lighter

Table 1. Baseline Patient Characteristics by Depth of Sedation During Surgery

Characteristic	No. (%)		
	Total (N = 200)	Lighter (n = 100)	Heavier (n = 100)
Age, mean (SD), y	81.8 (7.7)	81.6 (8.2)	82.0 (7.2)
Body mass index (calculated as weight in kilograms divided by height in meters squared), mean (SD)	25.0 (5.3)	25.2 (5.2)	24.8 (5.4)
Female	146 (73.0)	72 (72.0)	74 (74.0)
White race/ethnicity	194 (97.0)	97 (97.0)	97 (97.0)
Education level			
Less than high school	76 (38.0)	37 (37.0)	39 (39.0)
High school	76 (38.0)	37 (37.0)	39 (39.0)
Some college	28 (14.0)	16 (16.0)	12 (12.0)
College graduate or higher	20 (10.0)	10 (10.0)	10 (10.0)
Employment			
Retired/disabled	162 (81.0)	83 (83.0)	79 (79.0)
Working full-time/part-time	7 (3.5)	3 (3.0)	4 (2.0)
Homemaker	31 (15.5)	14 (14.0)	17 (17.0)
Residence			
Own home/family home	172 (86.0)	82 (82.0)	90 (90.0)
Assisted living/nursing home	7 (3.5)	6 (6.0)	1 (1.0)
Other	21 (10.5)	12 (12.0)	9 (9.0)
Reside with			
Alone	85 (42.5)	44 (44.0)	41 (41.0)
Spouse/partner	47 (28.0)	21 (27.0)	26 (29.0)
Family member (nonspouse)	52 (30.5)	23 (29.0)	29 (32.0)
Nonfamily member	1 (0.5)	0	1 (1.0)
Other	15 (3.0)	12 (6.0)	3 (0.0)
Status prior to surgery			
Charlson comorbidity index score, mean (SD)	1.5 (1.8)	1.5 (1.8)	1.6 (1.8)
American Society of Anesthesiologist rating $\geq 3$	139 (69.5)	63 (63.0)	76 (76.0)
PSMS, mean (SD)	4.61 (1.52)	4.66 (1.48)	4.56 (1.57)
IADL scale, mean (SD)	5.85 (2.22)	5.84 (2.17)	5.86 (2.28)
Alcohol, CAGE score $\geq 2$	27 (13.5)	7 (7.0)	20 (20.0)
Current cigarette smoker	31 (15.5)	18 (18.0)	13 (13.0)
Baseline cognitive testing			
Mini-Mental State Examination score, mean (SD)	24.3 (3.7)	24.4 (3.8)	24.2 (3.6)
Geriatric Depression score, mean (SD)	3.83 (3.48)	3.86 (3.71)	3.80 (3.25)
Clinical Dementia Rating score (n = 198/99/99)			
0	82 (41.4)	46 (46.5)	36 (36.4)
0.5	94 (47.5)	43 (43.4)	51 (51.5)
1	16 (8.1)	7 (7.1)	9 (9.1)
2	6 (3.0)	3 (3.0)	3 (3.0)
Subsyndromal delirium	13 (6.5)	4 (4.0)	9 (9.0)
Surgery characteristics			
Emergency department to surgery, mean (SD), d	1.2 (1.0)	1.3 (1.2)	1.2 (0.6)
Type of fracture			
Femoral neck	89 (44.5)	42 (42.0)	47 (47.0)
Inter/subtrochanteric	111 (55.5)	58 (58.0)	53 (53.0)
Type of procedure			
Hemiarthroplasty with/without cement	69 (34.5)	31 (31.0)	38 (38.0)
Total hip arthroplasty with/without cement	11 (5.5)	5 (5.0)	6 (6.0)
Cannulated screw	9 (4.5)	7 (7.0)	2 (2.0)
Intramedullary nail	110 (55.0)	57 (57.0)	53 (53.0)
Girdlestone	1 (0.5)	0 (0.0)	1 (1.0)

Abbreviations: CAGE, cut annoyed guilty eye; IADL, instrumental activities of daily living; PSMS, physical self-maintenance scale.

Table 2. Intraoperative and Postoperative Data by Depth of Sedation During Surgery

Characteristic	Mean (SD)		P Value
	Lighter (n = 100)	Heavier (n = 100)	
<b>Intraoperative</b>			
Modified Observer's Assessment of Alertness/Sedation scale from incision to the end of surgery <sup>a</sup>	4.1 (0.9)	0.2 (0.4)	<.001
Proportion of Modified Observer's Assessment of Alertness/Sedation Scale recordings that fall in the desired range (0-2 for heavier levels and 3-5 for lighter sedation levels) from incision to the end of surgery, %	89.9	97.7	
Bispectral Index (n = 197/98/99) from incision to the end of surgery <sup>b</sup>	82.3 (9.4)	57.0 (14.8)	<.001
Total propofol dose, mg	314.8 (185.0)	739.1 (342.8)	<.001
Total propofol dose by body weight, mg/kg	4.6 (2.3)	11.1 (4.4)	<.001
Incision to end of surgery, min	86.3 (31.0)	96.8 (36.9)	.03
Mean arterial pressure, mm Hg, (n = 199/99/100) from incision to the end of surgery	75.7 (11.2)	71.9 (9.5)	.01
Estimated blood loss	183.5 (154.5)	201.3 (146.9)	.41
Participants receiving an intraoperative RBC transfusion, No. (%)	1 (1.0)	3 (3.0)	.62
Participants receiving a blood transfusion, within 72 h postoperative, No. (%) <sup>c</sup>	37 (39.0)	38 (39.2)	.99
<b>Postoperative</b>			
Mean daily morphine equivalents by weight, mg/kg	0.13 (0.13)	0.16 (0.19)	.14
Mean daily pain score (Likert, 0-10)	3.4 (2.6)	3.9 (2.4)	.20
Postoperative admission to ICU, No. (%)	11 (11.0)	13 (13.0)	.74
Surgery until discharge, d	4.1 (2.6)	3.7 (2.5)	.27
Discharge location, No. (%)			
Rehabilitation center	85 (85.0)	89 (89.0)	.72
Nursing home/assisted living	1 (1.0)	0	
Own home/family home	11 (11.0)	9 (9.0)	
Other/death	3 (3.0)	2 (2.0)	


Abbreviations: ICU, intensive care unit; RBC, red blood cells.

<sup>a</sup> Sedation scores range from 0 (unresponsive) to 5 (wide awake).

<sup>b</sup> Bispectral index values range from 40 to 60 (general anesthesia) to 100 (wide awake).

<sup>c</sup> Of 192, there were 95 (49.5%) in the lighter sedation arm and 97 (50.5%) in the heavier sedation arm.

Figure 2. Kaplan-Meier Curve Showing Intention-to-Treat Analysis of Cumulative Incidence of Delirium During Postoperative Days 1 to 5 in the Lighter Sedation and Heavier Sedation Groups




electroencephalography criteria (bispectral index) to determine lighter or heavier sedation levels. In that study, lighter sedation levels decreased the prevalence of PD by 50% compared with heavier sedation levels. However, the bispectral index is not routinely used to manage sedation because of its poor correlation with sedation scores, particularly in ICU patients.<sup>21</sup> Additionally, several patients received multiple sedative agents, making the assessment of propofol-specific effects difficult. Furthermore, the total propofol dose was greater in the lighter sedation intervention arm of the previous study ( $4.6 \pm 2.3$  vs  $2.5 \pm 2.7$  mg/kg, respectively). Our propofol doses were higher, having administered additional propofol to perform spinal anesthesia rather than other sedative agents to avoid any confounding effects. Although the exact propofol dosage that is required to transition to delirium is unclear,<sup>4</sup> in vulnerable populations, propofol can precipitate delirium. Used as a sedative in the ICU, propofol is associated with rapidly reversible and persistent delirium.<sup>22</sup> Furthermore, hallucinations and delirium are reported after patients receive propofol doses similar to those administered in the STRIDE lighter sedation treatment arm.<sup>23,24</sup>

The trial was not sufficiently powered to detect any intervention effect that would allow a greater than 20.6% PD risk in the lighter sedation arm. The small overall PD reduction that was observed with lighter sedation levels is far from the level that was hypothesized in the power calculation. However, the hypothesized study power is not totally unfounded, as the larg-

sedation levels was attenuated. The selection of a sedation level can be an important decision in many patients as a means of decreasing PD. However, the benefits of lighter sedation levels may be overridden by baseline comorbidities.

The contribution of sedation depth to PD risk was examined in a previous randomized double-blind trial<sup>13</sup> that used

Figure 3. Charlson Comorbidity Index Scores



A, The adjusted hazard ratio showed that patients with the least comorbidity (Charlson comorbidity index = 0) were 2.3 times more likely to experience postoperative delirium after receiving heavier sedation levels than after receiving lighter sedation levels. B, Risk estimates for in-hospital postoperative delirium by treatment group and the associated 95% confidence intervals. Sample sizes (incident cases/total cases) are indicated in eTable 1 in Supplement 2. B, The difference in delirium risk after heavier and lighter sedation levels was not significant in patients with greater preoperative comorbidity. The dashed horizontal line indicates a 36.5% risk of in-hospital postoperative delirium, which was the estimated overall risk from the entire STRIDE sample. C, Percentage of patients stratified by Charlson comorbidity index score.

est CCI subgroup, a CCI score of 0, exhibited effects from sedation depth that were similar to those in previous studies.<sup>13</sup> The CCI score when treated as a continuous score modifies sedation depth effects on PD after adjusting for PD risk factors. At a CCI score of 0, lighter sedation levels were protective. The observation that higher CCI scores decreased the ability to prevent PD by modifying the depth of sedation is consistent with other studies that demonstrated that baseline vulnerabilities are the important independent drivers behind the development of PD.<sup>25</sup> We previously reported that dementia is a strong risk factor for PD in patients with hip fractures.<sup>26</sup> The high prevalence of baseline cognitive dysfunction in the STRIDE participants may have also influenced PD incidence, particularly at higher CCI scores. In addition, at a higher CCI, the estimate suggests a reverse situation in that heavier sedation levels might be protective. However, the trend was not significant and the estimate was unstable owing to small patient numbers at a high CCI. These factors limit our ability to investigate the reason for this reversal of effects and warrant additional studies. Several hypothesis that generate analysis were performed to elucidate the potential mechanisms that influenced the CCI interaction and intervention effect. The dementia CCI item alone did not predict PD after adjusting for baseline risk factors. When the CCI cardiovascular items were combined as a single score, there was significant intervention effect modification by this combined vascular score and risk of PD ( $\chi^2 = 4.07$ ;  $P = .04$ ), suggesting a cardiovascular mechanism.

### Strengths and Limitations

STRIDE is an efficacy trial that examined whether lighter sedation levels produces clinically meaningful effects in reducing PD incidence in a high-risk population. To best answer this question, we controlled as many variables as possible. The STRIDE

study strengths include using propofol as the only interventional drug. The high consent rate reduced selection bias. Compared with previous work, the methods were more rigorous. Four anesthesiologists anesthetized and managed all STRIDE cases in a consistent manner, and there were no protocol violations or group crossovers. Although a single-center study can lead to a loss of generalizability, we believe that protocol consistency and treated assignment administration outweighed this weakness. Additionally, hip fracture demographics are characterized by an older white female population.<sup>27</sup> The STRIDE population reflects these demographics and its PD prevalence is consistent with recent multicenter trials.<sup>28-30</sup> The perioperative delirium assessment was done in a systematic manner using standardized tools and a consensus panel. The randomization produced an excellent matching of participants in the 2 intervention groups. There were well-defined intraoperative differences in sedation levels between the intervention groups in terms of the propofol dose, OAAS, and bispectral index. Furthermore, bias was minimized in the delirium assessments and diagnostic process via a masking of assessors and consensus panel members to group assignments. The sample size was adequate to detect significant clinical effects.

One study weakness was the limiting of delirium testing to the first 5 postoperative days or until hospital discharge. Following hip fracture repair, the highest incidence of PD occurs on postoperative day 1,<sup>30,31</sup> as confirmed in Figure 2. Furthermore, delirium duration in STRIDE was comparable with other studies that examined longer follow-up periods.<sup>32</sup> Although some observations were cut short because of death, return to the operating room, or withdrawal, observations are available on every participant. Because most PD cases occurred on days 1 and 2 and the time-to-event approach treats the small numbers of observations that were cut short as censoring, the potential effect on our results would be minimal. Therefore, al-

though statistical inaccuracy due to a shorter follow-up in STRIDE cannot be completely ruled out, the likelihood of inaccuracy is small. We did not measure delirium subtypes, which could represent an unintended consequence of the intervention. Only patients who could safely undergo spinal anesthesia were included. Although the study results cannot necessarily be generalized to all hip fracture patients, in the United States approximately 40% of all hip fracture repairs are performed with spinal anesthesia.<sup>26</sup> The study results may not hold with anesthetic agents other than propofol. However, propofol is the most widely used drug for sedation. The STRIDE participants could reflect a healthier study population. However, the mean STRIDE CCI score<sup>33</sup> and distribution of CCI scores were consistent with the literature.<sup>34</sup> Several comorbidities that were included in the CCI calculation are associated with underlying cognitive dysfunction,<sup>35-37</sup> but our multivariate analysis controlled for baseline MMSE scores. Because CCI is not a complete surrogate measure for baseline risk factors of delirium, the modeling results may have been limited. A prespecified subgroup analysis to look for HTE must be interpreted carefully. Heterogeneity and comorbidity in this population may have limited our ability to detect significant overall effects. However, hetero-

geneity is the expected clinical norm, and when assessing for the interaction with comorbidity, we did find significant treatment effects in the low-comorbidity subgroup. Besides in-hospital PD outcomes, it is important to determine the intervention effects on long-term functional and cognitive outcomes. These data are in the process of analysis and will be reported in a separate article.

## Conclusions

In a subgroup analysis, the STRIDE results suggest that PD can be reduced in individuals with a CCI score of 0 by reducing sedation levels. The STRIDE trial suggests that the selection of sedation levels can be an important means of decreasing PD in many patients. However, the associated benefits of lighter sedation levels may be obscured by competing baseline comorbidities, placing patients at risk of developing PD. Given the STRIDE trial findings, the challenge for future research will be to determine the mechanisms and interactional relationships between comorbidities and precipitating risk factors for PD.

### ARTICLE INFORMATION

**Accepted for Publication:** May 13, 2018.

**Published Online:** August 8, 2018.  
doi:10.1001/jamasurg.2018.2602

**Author Affiliations:** Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland (Sieber, Jaber); Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland (Neufeld, Rosenberg); Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Hospital, Baltimore, Maryland (Gottschalk, Ouanes); Department of Neurosurgery, Johns Hopkins Hospital, Baltimore, Maryland (Gottschalk); Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, J. V. Brady Behavioral Biology Research Center, Johns Hopkins Bayview Campus, Baltimore, Maryland (Bigelow); Division of Geriatric Medicine and Gerontology, Psychiatry and Behavioral Sciences & Neuropathology, Johns Hopkins University School of Medicine, Baltimore, Maryland (Oh); Department of Orthopedic Surgery, University of Arkansas for Medical Sciences, Little Rock (Mears); Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland (Stewart); Adult and Trauma Surgery, Department of Orthopaedic Surgery, Johns Hopkins Bayview Medical Center, Baltimore, Maryland (Hasenboehler); Center for Clinical Trials and Evidence Synthesis, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (Li); Departments of Medicine (General Internal Medicine), Biostatistics, and Epidemiology, and Welch Center for Prevention, Epidemiology, and Clinical Research, The Johns Hopkins University, Baltimore, Maryland (Wang).

**Author Contributions:** Drs Sieber and Wang had full access to all the data in the study and take

responsibility for the integrity of the data and the accuracy of the data analysis.

**Concept and design:** Sieber, Neufeld, Gottschalk, Rosenberg, Mears, Stewart, Li, Wang.

**Acquisition, analysis, or interpretation of data:** Sieber, Neufeld, Gottschalk, Bigelow, Oh, Rosenberg, Mears, Stewart, Ouanes, Jaber, Hasenboehler, Wang.

**Drafting of the manuscript:** Sieber, Gottschalk, Bigelow, Oh, Rosenberg, Wang.

**Critical revision of the manuscript for important intellectual content:** All authors.

**Statistical analysis:** Sieber, Wang.

**Obtained funding:** Sieber, Gottschalk, Wang.

**Administrative, technical, or material support:** Sieber, Neufeld, Gottschalk, Bigelow, Oh, Mears, Stewart, Ouanes.

**Supervision:** Sieber, Neufeld, Bigelow.

**Other - classification interpretation of all included hip fractures:** Hasenboehler.

**Other - data management:** Stewart.

**Conflict of Interest Disclosures:** None reported.

**Funding/Support:** This research was supported by National Institute on Aging grant R01 AG033615.

**Role of the Funder/Sponsor:** The National Institute of Aging had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Reducible Research Statement:** Individual participant data that underlie the results reported in this article, study protocol, statistical analysis plan, and analytic code will be available for analysis after deidentification (text, tables, figures, and appendices) beginning 9 months and ending 36 months after article publication to researchers who provide a methodologically sound proposal to achieve the aims in the approved proposal. Proposals should be directed to [fsieber1@jhmi.edu](mailto:fsieber1@jhmi.edu).

To gain access, data requestors will need to sign a data access agreement.

**Additional Contributions:** We thank the assessment team (Kori Kindbom, MA, Rachel Burns, BS, and Michael Sklar, MA, Johns Hopkins University School of Medicine) for their follow-up of patients. These individuals were part of the study assessment and follow-up team and were compensated for their services through the study's National Institutes of Health grant. We also thank the data safety and monitoring board members (Jeffery Carson, MD, Rutgers University, Lee Fleisher, MD, University of Pennsylvania, Steve Epstein, MD, Georgetown University, Jay Magaziner, PhD, University of Maryland, Anne Lindblad, PhD, the Emmes Corporation, and Sarang Kim, MD, Rutgers University) for their time, effort, and oversight (see protocol) and Linda Sevier, Johns Hopkins Bayview Medical Center, for her preparation of the manuscript.

### REFERENCES

- Gleason LJ, Schmitt EM, Kosar CM, et al. Effect of delirium and other major complications on outcomes after elective surgery in older adults. *JAMA Surg*. 2015;150(12):1134-1140. doi:10.1001/jamasurg.2015.2606
- Leslie DL, Marcantonio ER, Zhang Y, Leo-Summers L, Inouye SK. One-year health care costs associated with delirium in the elderly population. *Arch Intern Med*. 2008;168(1):27-32. doi:10.1001/archinternmed.2007.4
- Pandharipande P, Ely EW. Sedative and analgesic medications: risk factors for delirium and sleep disturbances in the critically ill. *Crit Care Clin*. 2006;22(2):313-327, vii. doi:10.1016/j.ccc.2006.02.010
- Pandharipande P, Shintani A, Peterson J, et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. *Anesthesiology*. 2006;104(1):21-26. doi:10.1097/0000542-200601000-00005



5. Dubois MJ, Bergeron N, Dumont M, Dial S, Skrobik Y. Delirium in an intensive care unit: a study of risk factors. *Intensive Care Med*. 2001;27(8):1297-1304. doi:10.1007/s001340101017
6. Marcantonio ER, Goldman L, Mangione CM, et al. A clinical prediction rule for delirium after elective noncardiac surgery. *JAMA*. 1994;271(2):134-139. doi:10.1001/jama.1994.03510260066030
7. Sieber FE, Gottschalk A, Zakriya KJ, Mears SC, Lee H. General anesthesia occurs frequently in elderly patients during propofol-based sedation and spinal anesthesia. *J Clin Anesth*. 2010;22(3):179-183. doi:10.1016/j.jclinane.2009.06.005
8. Li T, Wieland LS, Oh E, et al. Design considerations of a randomized controlled trial of sedation level during hip fracture repair surgery: a strategy to reduce the incidence of postoperative delirium in elderly patients. *Clin Trials*. 2017;14(3):299-307. doi:10.1177/1740774516687253
9. Glass PS, Bloom M, Kearse L, Rosow C, Sebel P, Manberg P. Bispectral analysis measures sedation and memory effects of propofol, midazolam, isoflurane, and alfentanil in healthy volunteers. *Anesthesiology*. 1997;86(4):836-847. doi:10.1097/00000542-199704000-00014
10. Folstein MFFS, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res*. 1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6
11. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegel AP, Horwitz RI. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. *Ann Intern Med*. 1990;113(12):941-948. doi:10.7326/0003-4819-113-12-941
12. Trzepacz PT, Mittal D, Torres R, Canary K, Norton J, Jimerson N. Validation of the delirium rating scale-revised-98: comparison with the delirium rating scale and the cognitive test for delirium. *J Neuropsychiatry Clin Neurosci*. 2001;13(2):229-242. doi:10.1176/jnp.13.2.229
13. Sieber FE, Zakriya KJ, Gottschalk A, et al. Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair. *Mayo Clin Proc*. 2010;85(1):18-26. doi:10.4065/mcp.2009.0469
14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40(5):373-383. doi:10.1016/0021-9681(87)90171-8
15. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. *Gerontologist*. 1969;9(3):179-186. doi:10.1093/geront/9.3\_Part\_1.179
16. Ewing JA. Detecting alcoholism. The CAGE questionnaire. *JAMA*. 1984;252(14):1905-1907. doi:10.1001/jama.1984.03350140051025
17. Yesavage JA, Sheikh JI. 9/Geriatric Depression Scale (GDS). *Clin Gerontol*. 1986;5(1-2):165-173. doi:10.1300/J018v05n01\_09
18. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. *Neurology*. 1993;43(11):2412-2414. doi:10.1212/WNL.43.11.2412-a
19. Smith PJ, Attix DK, Weldon BC, Monk TG. Depressive symptoms and risk of postoperative delirium. *Am J Geriatr Psychiatry*. 2016;24(3):232-238. doi:10.1016/j.jagp.2015.12.004
20. Gruber-Baldini AL, Zimmerman S, Morrison RS, et al. Cognitive impairment in hip fracture patients: timing of detection and longitudinal follow-up. *J Am Geriatr Soc*. 2003;51(9):1227-1236. doi:10.1046/j.1532-5415.2003.51406.x
21. Hajat Z, Ahmad N, Andrzejowski J. The role and limitations of EEG-based depth of anaesthesia monitoring in theatres and intensive care. *Anaesthesia*. 2017;72(suppl 1):38-47. doi:10.1111/anae.13739
22. Patel SB, Poston JT, Pohlman A, Hall JB, Kress JP. Rapidly reversible, sedation-related delirium versus persistent delirium in the intensive care unit. *Am J Respir Crit Care Med*. 2014;189(6):658-665. doi:10.1164/rccm.201310-1815OC
23. Brown KE, Mirakhimov AE, Yedduka K, Kwatra MM. Propofol and the risk of delirium: exploring the anticholinergic properties of propofol. *Med Hypotheses*. 2013;81(4):536-539. doi:10.1016/j.mehy.2013.06.027
24. Balasubramaniam B, Park GR. Sexual hallucinations during and after sedation and anaesthesia. *Anaesthesia*. 2003;58(6):549-553. doi:10.1046/j.1365-2044.2003.03147.x
25. Inouye SK, Zhang Y, Jones RN, Kiely DK, Yang F, Marcantonio ER. Risk factors for delirium at discharge: development and validation of a predictive model. *Arch Intern Med*. 2007;167(13):1406-1413. doi:10.1001/archinte.167.13.1406
26. Lee HB, Mears SC, Rosenberg PB, Leoutsakos JM, Gottschalk A, Sieber FE. Predisposing factors for postoperative delirium after hip fracture repair in individuals with and without dementia. *J Am Geriatr Soc*. 2011;59(12):2306-2313. doi:10.1111/j.1532-5415.2011.03725.x
27. Friedman SM, Mendelson DA. Epidemiology of fragility fractures. *Clin Geriatr Med*. 2014;30(2):175-181. doi:10.1016/j.cger.2014.01.001
28. de Jonghe A, van Munster BC, Goslings JC, et al; Amsterdam Delirium Study Group. Effect of melatonin on incidence of delirium among patients with hip fracture: a multicentre, double-blind randomized controlled trial. *CMAJ*. 2014;186(14):E547-E556. doi:10.1503/cmaj.140495
29. Carson JL, Terrin ML, Noveck H, et al; FOCUS Investigators. Liberal or restrictive transfusion in high-risk patients after hip surgery. *N Engl J Med*. 2011;365(26):2453-2462. doi:10.1056/NEJMoa1012452
30. Gruber-Baldini AL, Marcantonio E, Orwig D, et al. Delirium outcomes in a randomized trial of blood transfusion thresholds in hospitalized older adults with hip fracture. *J Am Geriatr Soc*. 2013;61(8):1286-1295. doi:10.1111/jgs.12396
31. Duppils GS, Wikblad K. Acute confusional states in patients undergoing hip surgery: a prospective observation study. *Gerontology*. 2000;46(1):36-43. doi:10.1159/000022131
32. Bellelli G, Mazzola P, Morandi A, et al. Duration of postoperative delirium is an independent predictor of 6-month mortality in older adults after hip fracture. *J Am Geriatr Soc*. 2014;62(7):1335-1340. doi:10.1111/jgs.12885
33. Burgos E, Gómez-Arnau JJ, Díez R, Muñoz L, Fernández-Guisasaola J, García del Valle S. Predictive value of six risk scores for outcome after surgical repair of hip fracture in elderly patients. *Acta Anaesthesiol Scand*. 2008;52(1):125-131. doi:10.1111/j.1399-6576.2007.01473.x
34. Johnson DJ, Greenberg SE, Sathiyakumar V, et al. Relationship between the Charlson Comorbidity Index and cost of treating hip fractures: implications for bundled payment. *J Orthop Traumatol*. 2015;16(3):209-213. doi:10.1007/s10195-015-0337-z
35. Yohannes AM, Chen W, Moga AM, Leroi I, Connolly MJ. Cognitive impairment in chronic obstructive pulmonary disease and chronic heart failure: a systematic review and meta-analysis of observational studies. *J Am Med Dir Assoc*. 2017;18(5):451.e1-451.e11. doi:10.1016/j.jamda.2017.01.014
36. Yaffe K, Ackerson L, Kurella Tamura M, et al; Chronic Renal Insufficiency Cohort Investigators. Chronic kidney disease and cognitive function in older adults: findings from the chronic renal insufficiency cohort cognitive study. *J Am Geriatr Soc*. 2010;58(2):338-345. doi:10.1111/j.1532-5415.2009.02670.x
37. Eggermont LH, de Boer K, Muller M, Janschke AC, Kamp O, Scherder EJ. Cardiac disease and cognitive impairment: a systematic review. *Heart*. 2012;98(18):1334-1340. doi:10.1136/heartjnl-2012-301682